Table 3 Severity indexes of the disease in our COVID-19 patients
Severity indexes | COVID-19 patients | |||
|---|---|---|---|---|
All patients (n = 62) | Group A (n = 38) FT3 ≤ 1.7 pg/ml | Group B (n = 24) FT3 > 1.7 pg/ml | P value | |
Thyroid function | ||||
FT3 (pg/ml) | 1.7 ± 0.6 | 1.2 ± 0.2 | 2.1 ± 0.6 | ≪ 0.005 |
FT4 (ng/dl) | 1.1 ± 0.2 | 1.0 ± 0.3 | 1.1 ± 0.1 | NS |
TSH (µIU/ml) | 1.0 ± 0.9 | 0.7 ± 0.8 | 1.3 ± 1.1 | 0.01 |
Hemocromocytometric parameters | ||||
RBC (×106cells/µl) | 4.0 ± 0.7 | 3.9 ± 0.7 | 4.2 ± 0.7 | 0.06 |
HGB (g/dl) | 11.9 ± 1.9 | 11.5 ± 1.9 | 12.5 ± 1.9 | 0.03 |
WBC (×103cells/µl) | 8.6 ± 3.9 | 9.2 ± 4.4 | 7.7 ± 2.9 | 0.07 |
ANC (×103cells/mm3) | 6.5 ± 3.4 | 7.6 ± 3.5 | 5.0 ± 2.5 | 0.002 |
ALC (×103cells/mm3) | 1.4 ± 1.6 | 1.1 ± 1.9 | 1.7 ± 0.8 | 0.09 |
NLR | 8.2 ± 7.9 | 11.2 ± 8.7 | 3.4 ± 2.8 | 0.00004 |
dNLR | 5.8 ± 4.4 | 7.4 ± 4.8 | 3.3 ± 1.6 | 0.0001 |
Lymphocytes subpopulations | ||||
CD45+ (cells/µl) | 1034 ± 1147.6 | 902.4 ± 1235.3 | 1341.3 ± 871.6 | NS |
CD19+ (cells/µl) | 251.9 ± 973.4 | 293.4 ± 1164.2 | 155.9 ± 135.0 | NS |
CD3+ (cells/µl) | 629.9 ± 500.8 | 467.1 ± 234.9 | 1006.4 ± 721.5 | 0.0001 |
CD45+CD3+CD8+ (cells/µl) | 211.8 ± 169.4 | 174.9 ± 134.5 | 297.2 ± 212.1 | 0.007 |
CD45+CD3+CD4+ (cells/µl) | 402.2 ± 366.2 | 282.2 ± 158.7 | 686.2 ± 513.9 | 0.0005 |
CD4+/CD8+ ratio | 2.4 ± 1.6 | 2.22 ± 1.61 | 2.88 ± 1.6 | 0.09 |
CD3−CD16+CD56+ (cells/µl) | 115.3 ± 83.5 | 99.7 ± 60.7 | 150.9 ± 115.7 | 0.02 |
Serum markers of inflammation | ||||
APC (×103cells/µl) | 215.1 ± 111.2 | 186.0 ± 96.4 | 261.1 ± 119.1 | 0.005 |
PLR | 231.4 ± 136.4 | 254.0 ± 131.2 | 195.5 ± 139.3 | 0.05 |
PCT (ng/ml) | 3.3 ± 17.2 | 4.8 ± 20.9 | 0.2 ± 0.3 | NS |
hs-CRP (mg/dl) | 10.0 ± 13.1 | 12.7 ± 14.5 | 5.1 ± 8.0 | 0.006 |
Serum markers of tissue damages | ||||
CK (U/l) | 81.0 ± 98.7 | 82.1 ± 104.1 | 79.4 ± 91.6 | NS |
CK-MB (ng/ml) | 1.2 ± 1.4 | 1.4 ± 1.7 | 1.1 ± 0.8 | NS |
Bilirubin (mg/dl) | 0.6 ± 0.6 | 0.7 ± 0.7 | 0.5 ± 0.2 | NS |
hs-cTnI (pg/ml) | 41.0 ± 93.3 | 59.8 ± 110.8 | 9.7 ± 16.5 | 0.02 |
Creatinine (mg/dl) | 1.2 ± 1.4 | 1.4 ± 1.7 | 0.9 ± 0.4 | 0.09 |
Ferritin (ng/ml) | 769.2 ± 743.2 | 1085.6 ± 950.8 | 495.5 ± 482.8 | 0.009 |
LDH (U/l) | 300.1 ± 101.8 | 328.2 ± 105.7 | 253.6 ± 79.1 | 0.002 |
Serum coagulation markers | ||||
Fibrinogen (mg/dl) | 555.2 ± 251.8 | 602.4 ± 269.0 | 476.5 ± 202.9 | 0.03 |
PT (s) | 13.8 ± 4.7 | 13.3 ± 1.7 | 14.6 ± 7.2 | NS |
D-dimer (ng/ml) | 857.8 ± 1055.8 | 1038.6 ± 964.6 | 582.3 ± 1050.1 | 0.04 |
Serum immunological markers | ||||
IL-6 (pg/ml) | 181.3 ± 456.7 | 232.1 ± 580.6 | 103.9 ± 94.4 | NS |
Severity scores of lung damage | ||||
LIPI score | 1.5 ± 0.6 | 1.8 ± 0.4 | 1.2 ± 0.6 | 0.00003 |
Radiological severity scores of lung damage | ||||
TSS score | 8.1 ± 4.3 | 9.6 ± 3.9 | 5.7 ± 3.9 | 0.0004 |
Clinical severity score | ||||
SOFA score | 2.8 ± 1.8 | 3.3 ± 1.7 | 2.3 ± 1.7 | 0.001 |